Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1CNS 1

Conditions

Breast Neoplasms 2Wilms Tumor 1Triple Negative Breast Neoplasms 1Sarcoma, Synovial 1Sarcoma 1Rhabdomyosarcoma 1Prostatic Neoplasms 1Pleuropulmonary blastoma 1Pathologic Complete Response 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neurofibrosarcoma 1Neuroblastoma 1Neoplasms 1Hemangiosarcoma 1

Interventions

Filgrastim 10Cyclophosphamide 8X-Rays 6Phantoms, Imaging 6Granulocyte Colony-Stimulating Factor 6Temozolomide 5Specimen Handling 5Magnetic Resonance Spectroscopy 5Ifosfamide 5Carboplatin 5Vincristine 4Radiotherapy 4Peripheral Blood Stem Cell Transplantation 4Nuclear Medicine Department, Hospital 4Melphalan 4Etoposide 4Busulfan 4Topotecan 3Thiotepa 3Stem Cell Transplantation 3Mesna 3Cisplatin 3Biopsy 3ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2sargramostim 2palbociclib 2olaparib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Wilms Tumor × Ado-Trastuzumab Emtansine × Sarcoma × Clear all
NCT02452554 2022-01-13

Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma

Children's Oncology Group

Phase 2 Completed
62 enrolled 15 charts
CNSGenitourinarySarcoma

Pleuropulmonary blastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Synovial, Neurofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡